CDPPB
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.222.673 Edit this at Wikidata |
| Chemical and physical data | |
| Formula | C23H18N4O |
| Molar mass | 366.424 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| ☒NcheckY (what is this?) (verify) | |
CDPPB is a drug used in scientific research which acts as a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5.[1] [2] [3] It has antipsychotic effects in animal models,[4] and mGluR5 modulators are under investigation as potential drugs for the treatment of schizophrenia,[5] as well as other applications.[6] [7]
References
[edit ]- ^ Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR (November 2004). "Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo". Journal of Medicinal Chemistry. 47 (24): 5825–8. doi:10.1021/jm049400d. PMID 15537338.
- ^ de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ (June 2006). "Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes". Journal of Medicinal Chemistry. 49 (11): 3332–44. doi:10.1021/jm051252j. PMID 16722652.
- ^ Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, Conn PJ (May 2007). "Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses". Molecular Pharmacology. 71 (5): 1389–98. doi:10.1124/mol.106.032425. PMID 17303702. S2CID 7004830.
- ^ Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL (April 2005). "A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models". The Journal of Pharmacology and Experimental Therapeutics. 313 (1): 199–206. doi:10.1124/jpet.104.079244. PMID 15608073. S2CID 14946765.
- ^ Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Sur C, Kinney GG (2006). "Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia". Current Topics in Medicinal Chemistry. 6 (8): 771–85. doi:10.2174/156802606777057599. PMID 16719816.
- ^ Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B (October 2007). "Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex". Biological Psychiatry. 62 (7): 739–46. doi:10.1016/j.biopsych.200612003. PMC 2910402 . PMID 17511968.
- ^ Gass JT, Olive MF (April 2009). "Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory". Biological Psychiatry. 65 (8): 717–20. doi:10.1016/j.biopsych.200811001. PMC 2870714 . PMID 19100966.
Stub icon
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://en.wikipedia.org/w/index.php?title=CDPPB&oldid=1269670354"